• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Who should be prioritized for HCV antiviral treatment? A cost-effectiveness analysis including individual and population prevention benefits 
    •   QMRO Home
    • Blizard Institute
    • Centre for Immunobiology
    • Who should be prioritized for HCV antiviral treatment? A cost-effectiveness analysis including individual and population prevention benefits
    •   QMRO Home
    • Blizard Institute
    • Centre for Immunobiology
    • Who should be prioritized for HCV antiviral treatment? A cost-effectiveness analysis including individual and population prevention benefits
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Who should be prioritized for HCV antiviral treatment? A cost-effectiveness analysis including individual and population prevention benefits

    Volume
    60
    Pagination
    1042A - 1042A
    ISSN
    0270-9139
    Metadata
    Show full item record
    Authors
    Martin, NK; Vickerman, P; Dore, GJ; Grebely, J; Foster, GR; Miners, A; Hutchinson, S; Goldberg, DJ; Martin, TC
    URI
    http://qmro.qmul.ac.uk/xmlui/handle/123456789/7003
    Collections
    • Centre for Immunobiology [921]
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.